Research programme: monoclonal antibody therapeutics - Dyadic International
Alternative Names: monoclonal antibody therapeutics - Dyadic InternationalLatest Information Update: 05 Feb 2025
At a glance
- Originator Dyadic International
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Malaria; Respiratory syncytial virus infections